Carcidiag Biotech, one of the most innovative start-ups in Creuse, risks compulsory liquidation

“Today, we have completed our development phase. Our products are ready to be commercialized, they have their CE mark, we have a place in Guéret that allows us to produce clinical diagnostic kits, we have the product catalog, the brochures commercial, everything is ready,” he explains with a certain pride. Vincent Carré, founder and president of the company Carcidiag, whose biotechnologies are the subject of publication in scientific journals.

However, the start-up specialized in cancer screening suffered an abrupt halt in its promising development. “We don’t really have the luck to be very honest,” continues, more bitterly, its creator.

A start-up that advances the fight against cancer created in Creuse with severance pay

Biotech products for oncology ready to be commercialized

During the Covid pandemic, the start-up put its cancer activities on hold to develop Covid serology tests and Covid tests for animals, at the request of a company from Lyon.

“We developed products that in the end did not find takers, we lost time and money, slices Vincent Carré. We have no more money and therefore we can no longer launch the commercialization of our products…

Vincent Carre (founder and president of Carcidiag)

To start this final phase, it would be necessary to finance the presence at congresses, all over the world, “which is very expensive”.

And the situation multiplied the difficulties to be overcome. “We benefited from a tranche of the loan guaranteed by the State instituted during the Covid but it no longer exists and the banks have informed us that they will not finance the second tranche which amounts to 300,000, 400,000 euros…”. The Montpellier company, which was interested in investing in Carcidiag, going as far as the stage of the letter of intent (LOI) to acquire the Gueret company at the end of 2022, was finally cooled by the implementation of the safeguard procedure for the company. , which happened in July


Receive our eco newsletter by email and find the latest news from economic players in your region.

NL {“path”:”mini-inscription/MT_Decideur”,”accessCode”:”14183942″,”allowGCS”:”true”,”bodyClass”:”ripo_generic”,”contextLevel”:”KEEP_ALL”,”filterMotsCles”: “1|3|13|97|1957″,”gabarit”:”generic”,”hasEssentiel”:”true”,”idArticle”:”4183942″,”idArticlesList”:”4183942″,”idDepartment”:”242 “,”idZone”:”12813″,”motsCles”:”1|3|13|97|1957″,”premium”:”true”,”pubs”:”banniere_haute|article”,”site”:”MT “,”sousDomain”:”www”,”urlTitle”:”carcidiag-biotech-one-of-the-most-innovative-start-ups-in-creuse-risk-la-liquidation-judiciaire”}

In Creuse, the Carcidiag company should produce 50,000 Covid diagnostic kits per summer day

But dry cash…

“We are in a mandatory rescue procedure, with an appointed administrator, because we really do not know how to do otherwise, explains Vincent Carré. We have been rowing for a year to find money, already to finish the team, confides the president of Carcidiag who had to leave with four people of the twelve that make up the company, “to limit the expenses as much as possible. …” While they are looking, almost desperately, for an investor who will support them in this marketing phase or a buyer who will buy the whole company.
This Tuesday, the situation was examined by the administrative court of Limoges which must decide, this Thursday, on a placement in recovery or a liquidation. “If we go into the recovery, we will gain some time, we would have until October, we can do “publicity”, which we could not before, to say that Carcidiag is looking for a buyer.”


And Vincent Carré calls to all possible interested parties, private and public investors, companies, employers or communities…

“We are looking for people who can help us commercialize our products. Today, we need one million to 1.5 million euros in two years to structure the company on the market and be autonomous, less if we find an industrial partner … We want to find a peaceful and lasting solution.” Vincent Carre

(founder and president of Carcidiag)

Carcidiag thought he had already taken on his biggest challenge by setting up in the heart of the Creuse, but he still has a higher step to climb. “It was a challenge to launch a start-up in this sector in Creuse. As soon as we see investors, they ask us why we are not in Lyon, Bordeaux. We had to fight to be here, we developed everything we said we would do and then it all fell apart, it’s infuriating…”

Designed in Creuse, the 1st cancer stem cell detection kit will be marketed in September

A judicial liquidation would mean “we lose everything, the patents, etc. everything goes into oblivion. Ten years of scrapping, a lot of time, personal investment, sacrifices”, remembers Vincent Carré who, despite everything, does not lose faith. he wants us to stop at every galley we meet, because we have met! Today we are ready, it would be too stupid to stop everything now.”

That should last until the end of September.

A biotech nugget just waiting to grow
Clinical diagnostics, basic research, Carcidiag has developed products that significantly advance cancer screening and treatment.
“Cancer, we talk about it a lot, but no one puts more money into it”, regrets Vincent Carré, whose company has designed a range of kits aimed at the clinical diagnosis of patients.


“They allow us to define the aggressiveness of a cancer, which directs the therapy implemented,” explains the founding president of Carcidiag. We also offer products that are of interest for fundamental research. A technology has been developed that allows the detection of cancer stem cells, those that are at the origin of cancers and that initiate and spread cancer in the form of metastases, he continues. Nobody does that today, it’s completely new AND it works! “.

The small start-up from Guéré is today at the forefront of biotechnologies dedicated to oncology. A first scientific publication takes its results this summer, recognized by its peers and another is to come at the beginning of the year. However, it is impossible to market their products. “This recognition is one of the things you need to start marketing. We are right in the middle of what is done today in diagnosis, on something that works. I do not understand why it does not work.”

Vincent Carre

(founder and president of Carcidiag)
And the market that opens is as promising as Carcidiag’s research, if it can reassure potential investors. “It is a global market, and we have taken patents accordingly. We will no longer be on a few thousand euros in invoices.”
Julie Ho Hoa

Leave a Comment

Your email address will not be published. Required fields are marked *